Home LiteratureArticle Details
PMID: 19325623 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Targeting the ubiquitin system in cancer therapy.

Nature ·Vol. 458 ·No. 7237 ·2009-03-26 ·Pages 438-44

Hoeller D, Dikic I

Abstract

The ubiquitin system is a network of proteins dedicated to the ubiquitylation of cellular targets and the subsequent control of numerous cellular functions. The deregulation of components of this elaborate network leads to human pathogenesis, including the development of many types of tumour. Alterations in the ubiquitin system that occur during the initiation and progression of cancer are now being uncovered, and this knowledge is starting to be exploited for both molecular diagnostics and the development of novel strategies to combat cancer.

MeSH Terms
Apoptosis/drug effects Humans Neoplasms/blood supply,drug therapy,enzymology,pathology Neovascularization, Pathologic/drug therapy Proteasome Endopeptidase Complex/metabolism Proteasome Inhibitors SUMO-1 Protein/metabolism Ubiquitin/metabolism Ubiquitin-Protein Ligases/antagonists & inhibitors,metabolism
Chemicals
Proteasome Inhibitors SUMO-1 Protein Ubiquitin Ubiquitin-Protein Ligases Proteasome Endopeptidase Complex
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Hoeller Daniela
Division of Medical Biochemistry, Innsbruck Medical University, Biocenter, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria.
Dikic Ivan
References (75)
75 references, click to expand
  1. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
    Clin Cancer Res. 2003 Mar;9(3):1145-54 PMID: 12631620
  2. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s PMID: 17255293
  3. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.
    J Clin Invest. 2005 Oct;115(10):2673-8 PMID: 16200201
  4. IAPs: what's in a name?
    Mol Cell. 2008 Apr 25;30(2):123-35 PMID: 18439892
  5. Fbw7 and Usp28 regulate myc protein stability in response to DNA damage.
    Cell Cycle. 2007 Oct 1;6(19):2327-31 PMID: 17873522
  6. Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series.
    EMBO Rep. 2008 Jun;9(6):536-42 PMID: 18516089
  7. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.
    Nature. 2008 Oct 9;455(7214):813-7 PMID: 18716620
  8. The ubiquitin-specific protease USP28 is required for MYC stability.
    Nat Cell Biol. 2007 Jul;9(7):765-74 PMID: 17558397
  9. Deubiquitylation and regulation of the immune response.
    Nat Rev Immunol. 2008 Jul;8(7):501-11 PMID: 18535581
  10. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection.
    Nat Struct Mol Biol. 2005 Jan;12(1):67-74 PMID: 15608651
  11. Bortezomib in the front-line treatment of multiple myeloma.
    Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72 PMID: 18588451
  12. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53.
    Nat Cell Biol. 2007 Apr;9(4):428-35 PMID: 17369817
  13. Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells.
    Oncogene. 2006 Oct 26;25(50):6672-7 PMID: 16732328
  14. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain.
    Science. 2004 Oct 1;306(5693):117-20 PMID: 15459393
  15. Ubiquitin signalling in the NF-kappaB pathway.
    Nat Cell Biol. 2005 Aug;7(8):758-65 PMID: 16056267
  16. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis.
    Nat Rev Cancer. 2006 Oct;6(10):776-88 PMID: 16990855
  17. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors.
    Am J Pathol. 2000 May;156(5):1693-700 PMID: 10793080
  18. P53 and prognosis: new insights and further complexity.
    Cell. 2005 Jan 14;120(1):7-10 PMID: 15652475
  19. Ubiquitin ligases: cell-cycle control and cancer.
    Nat Rev Cancer. 2006 May;6(5):369-81 PMID: 16633365
  20. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
    Blood. 2007 Jul 1;110(1):267-77 PMID: 17356134
  21. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
    Cell. 1996 Aug 9;86(3):353-64 PMID: 8756718
  22. MDM2 is a central node in the p53 pathway: 12 years and counting.
    Curr Cancer Drug Targets. 2005 Feb;5(1):3-8 PMID: 15720184
  23. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
    Cancer Cell. 2005 Jun;7(6):547-59 PMID: 15950904
  24. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
    Nat Med. 2004 Dec;10(12):1321-8 PMID: 15558054
  25. Ubiquitination regulates PTEN nuclear import and tumor suppression.
    Cell. 2007 Jan 12;128(1):141-56 PMID: 17218261
  26. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.
    Nature. 2004 Aug 5;430(7000):694-9 PMID: 15258597
  27. Mechanisms, biology and inhibitors of deubiquitinating enzymes.
    Nat Chem Biol. 2007 Nov;3(11):697-705 PMID: 17948018
  28. Mechanisms underlying ubiquitination.
    Annu Rev Biochem. 2001;70:503-33 PMID: 11395416
  29. MDM2 inhibitors for cancer therapy.
    Trends Mol Med. 2007 Jan;13(1):23-31 PMID: 17126603
  30. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.
    Cell. 2007 Jan 12;128(1):129-39 PMID: 17218260
  31. The development of proteasome inhibitors as anticancer drugs.
    Cancer Cell. 2004 May;5(5):417-21 PMID: 15144949
  32. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
    Blood. 2008 Mar 1;111(5):2765-75 PMID: 18057228
  33. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination.
    J Biol Chem. 2007 May 11;282(19):14616-25 PMID: 17371868
  34. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.
    Cell. 2007 Nov 16;131(4):682-93 PMID: 18022363
  35. Receptor downregulation and multivesicular-body sorting.
    Nat Rev Mol Cell Biol. 2002 Dec;3(12):893-905 PMID: 12461556
  36. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
    Nat Rev Cancer. 2006 Mar;6(3):184-92 PMID: 16453012
  37. A genomic and functional inventory of deubiquitinating enzymes.
    Cell. 2005 Dec 2;123(5):773-86 PMID: 16325574
  38. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes.
    BMC Biochem. 2007 Nov 22;8 Suppl 1:S9 PMID: 18047746
  39. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas.
    Blood. 1999 Jun 1;93(11):3601-9 PMID: 10339464
  40. Drug discovery in the ubiquitin-proteasome system.
    Nat Rev Drug Discov. 2006 Jul;5(7):596-613 PMID: 16816840
  41. p53 ubiquitination: Mdm2 and beyond.
    Mol Cell. 2006 Feb 3;21(3):307-15 PMID: 16455486
  42. Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
    Int J Clin Oncol. 2007 Oct;12(5):318-26 PMID: 17929113
  43. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway.
    Mol Cell. 2005 Feb 4;17(3):331-9 PMID: 15694335
  44. Monoubiquitination: the signal for p53 nuclear export?
    Cell Cycle. 2004 Apr;3(4):436-8 PMID: 14976431
  45. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
    Mol Cancer Ther. 2008 Aug;7(8):2298-307 PMID: 18723477
  46. A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.
    J Biol Chem. 2007 Apr 6;282(14):10180-9 PMID: 17287209
  47. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation.
    J Biol Chem. 2008 Sep 5;283(36):24295-9 PMID: 18621737
  48. IAPs, RINGs and ubiquitylation.
    Nat Rev Mol Cell Biol. 2005 Apr;6(4):287-97 PMID: 15803136
  49. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
    Blood. 2008 Feb 1;111(3):1654-64 PMID: 18006697
  50. Proteasome subunit Rpn13 is a novel ubiquitin receptor.
    Nature. 2008 May 22;453(7194):481-8 PMID: 18497817
  51. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
    Cell. 2006 May 19;125(4):665-77 PMID: 16713561
  52. Alternative UPS drug targets upstream the 26S proteasome.
    Int J Biochem Cell Biol. 2008;40(6-7):1126-40 PMID: 18203645
  53. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
    Br J Cancer. 2006 Jul 3;95(1):42-8 PMID: 16804528
  54. Nuclear factor-kappaB in cancer development and progression.
    Nature. 2006 May 25;441(7092):431-6 PMID: 16724054
  55. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities.
    Nature. 2007 Apr 19;446(7138):876-81 PMID: 17443180
  56. Patented small molecule inhibitors in the ubiquitin proteasome system.
    BMC Biochem. 2007 Nov 22;8 Suppl 1:S14 PMID: 18047738
  57. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Cancer Res. 2007 Feb 15;67(4):1783-92 PMID: 17308121
  58. Role of proteasomes in disease.
    BMC Biochem. 2007 Nov 22;8 Suppl 1:S3 PMID: 18047740
  59. Ubiquitin-binding domains.
    Biochem J. 2006 Nov 1;399(3):361-72 PMID: 17034365
  60. Proteasome-independent functions of ubiquitin in endocytosis and signaling.
    Science. 2007 Jan 12;315(5809):201-5 PMID: 17218518
  61. Transcription-independent pro-apoptotic functions of p53.
    Curr Opin Cell Biol. 2005 Dec;17(6):631-6 PMID: 16226451
  62. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
    J Med Chem. 2008 Feb 28;51(4):1068-72 PMID: 18247547
  63. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
    Nat Cell Biol. 2008 May;10(5):547-55 PMID: 18408733
  64. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer.
    Nat Rev Cancer. 2008 Jun;8(6):438-49 PMID: 18500245
  65. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
    Cancer Cell. 2008 Jul 8;14(1):23-35 PMID: 18598941
  66. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
    Nat Cell Biol. 2008 May;10(5):538-46 PMID: 18408734
  67. Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis.
    Science. 2005 Dec 16;310(5755):1821-4 PMID: 16357261
  68. DNA damage: ubiquitin marks the spot.
    Nat Struct Mol Biol. 2008 Jan;15(1):20-2 PMID: 18176551
  69. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.
    J Biol Chem. 2001 May 4;276(18):14537-40 PMID: 11278247
  70. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line.
    Chem Biol. 2003 Sep;10(9):837-46 PMID: 14522054
  71. The ubiquitin system.
    Annu Rev Biochem. 1998;67:425-79 PMID: 9759494
  72. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization.
    Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8585-90 PMID: 18562292
  73. Ubiquitylation and cell signaling.
    EMBO J. 2005 Oct 5;24(19):3353-9 PMID: 16148945
  74. The HECT family of E3 ubiquitin ligases: multiple players in cancer development.
    Cancer Cell. 2008 Jul 8;14(1):10-21 PMID: 18598940
  75. Proteolysis. The proteasome: a protein-degrading organelle?
    Curr Biol. 1995 Aug 1;5(8):854-8 PMID: 7583140
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
DOI
10.1038/nature07960
Published
2009-03-26
Pages
438-44
Language
English
Region
England
NLM ID
0410462
Subset
IM
External Links
PubMed source DOI: 10.1038/nature07960 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2